High expression of LEF1 correlates with poor prognosis in solid tumors, but not blood tumors: a meta-analysis.

ABSTRACT: Previously published studies have indicated that lymphoid enhancer-binding factor 1 (LEF1) expression could be recognized as a valuable biomarker to evaluate clinical outcome for various types of malignant cancer, but the results remained controversial. Therefore, we conducted this meta-analysis to pool the published estimates and discuss the relationship of LEF1 expression with cancer prognosis. Five electronic databases Pubmed, Web of Science, Embase, CNKI, and Wanfang were systematically searched for eligible literatures. Hazard ratios (HRs) and 95% confidence intervals (CIs) from the included studies were combined to estimate the effect of LEF1 expression on cancer patients' survival. Eleven original studies met the criteria and were enrolled for analysis. The results indicated that co

SUBMITTER: Yang X 

PROVIDER: S-EPMC7468095 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature